NCT05847517 (MAIDEN) is a Phase 3 clinical trial of Metoprolol Injection in Acute Respiratory Distress Syndrome (ARDS), sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER).

Who is sponsoring NCT05847517?

NCT05847517 is sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER).

What drugs are being tested in NCT05847517?

Interventions in NCT05847517: Metoprolol Injection, saline 0.9%.

What condition does NCT05847517 study?

NCT05847517 studies Acute Respiratory Distress Syndrome (ARDS).

Is NCT05847517 still recruiting?

NCT05847517 is currently terminated. Last updated 29 May 2026.

Last reviewed 2026-05-29 · How we verify

NCT05847517: MAIDEN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomised, Double-blind, Placebo-controlled Clinical Trial to Evaluate the to Assess the Efficacy of Intravenous Metoprolol in Patients With Acute Respiratory Distress Syndrome (ARDS).

Terminated Phase 3 Last updated 29 May 2026

What this trial tests

Phase 3 trial testing Metoprolol Injection in Acute Respiratory Distress Syndrome (ARDS) in 14 participants. Terminated before completion.

Timeline

10 July 2024

Primary endpoint
6 October 2025

6 October 2025

Quick facts

Lead sponsor	Consorcio Centro de Investigación Biomédica en Red (CIBER)
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	14
Start date	10 July 2024
Primary completion	6 October 2025
Estimated completion	6 October 2025
Sites	12 locations across Spain

Drugs / interventions tested

Metoprolol Injection
saline 0.9% — full drug profile →

Conditions studied

Acute Respiratory Distress Syndrome (ARDS) — all drugs for Acute Respiratory Distress Syndrome (ARDS) →

Sponsor

Consorcio Centro de Investigación Biomédica en Red (CIBER) — full company profile →

Who can join

Adults 18 to 80, any sex, with Acute Respiratory Distress Syndrome (ARDS). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

days alive and free of invasive mechanical ventilation during the first 28 days.
Time frame: 28 days
Hierarchical composite outcome "Alive and ventilator-free days at 28 days" (win ratio approach)

Sponsor's own description

Randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy of intravenous metoprolol in patients with Acute Respiratory Respiratory Distress Syndrome (ARDS).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Mitochondrial network dynamics in pulmonary disease: Bridging the gap between inflammation, oxidative stress, and bioenergetics.
Pokharel MD, Garcia-Flores A, Marciano D, Franco MC, et al · · 2024 · cited 73× · PMID 38295575 · DOI 10.1016/j.redox.2024.103049
Mechanisms of alveolar type II epithelial cells' mitochondrial quality control during acute lung injury/acute respiratory distress syndrome: bridging the gap between oxidative stress, inflammation, and fibrosis.
Zeng L, Yan J. · · 2025 · cited 1× · PMID 41178984 · DOI 10.3389/fphys.2025.1684729
Pharmacogenomics and chronotherapy of drug-induced cardioprotection in acute myocardial infarction.
Clemente-Moragón A, Suárez-Barrientos A, Gómez Tech M, López-Palomar Tech LP, et al · · 2025 · PMID 41290608 · DOI 10.1038/s41467-025-65385-9

Verify or expand the search:

Other trials of Metoprolol Injection

Trials testing the same drug.

NCT05768542 — Sympathetic and Vascular Function in Takotsubo Syndrome · Phase 1, PHASE2 · completed

Other recruiting trials for Acute Respiratory Distress Syndrome (ARDS)

Currently open trials in the same condition.

NCT07395076 — Study of the Immunological Pathophysiological Mechanisms Associated With Acute Respiratory Distress Syndrome · recruiting
NCT07504731 — Trunk Inclination, Positive End-expiratory Pressure, and Lung Recruitability · recruiting
NCT07414056 — Turning Ratios Into Prognosis: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS · recruiting
NCT07123961 — Pediatric Acute Respiratory Distress Syndrome (ARDS) Management Trial · Phase 2 · recruiting
NCT06844617 — A Trial of Staff Time With Proned Patients in the ICU Using the 'BathMat' · NA · recruiting

Other Consorcio Centro de Investigación Biomédica en Red (CIBER) trials

Trials by the same sponsor.

NCT07314177 — Effects of Three Dietary Strategies on Body Composition and Metabolic Health in Adults With Overweight or Obesity · NA · completed
NCT06060886 — Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis · Phase 4 · unknown
NCT06055504 — Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1) · NA · recruiting
NCT04504968 — Effectiveness of a Multimodal Intervention on Function in Older Frail People With Diabetes in Latinamerican · NA · unknown
NCT04457505 — One Year Follow-ups of Patients Admitted to Spanish Intensive Care Units Due to COVID-19 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05847517 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Consorcio Centro de Investigación Biomédica en Red (CIBER)
Last refreshed: 29 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05847517.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing